M1 receptor agonists(Muscarinic acetylcholine receptor M1 agonists), M4 receptor agonists(Muscarinic acetylcholine receptor M4 agonists), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Other DiseasesNervous System Diseases

Active Indication

SchizophreniaAcute schizophreniaAlzheimer Disease+ [1]

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Karuna Therapeutics, Inc.

Zai Lab (Shanghai) Co., Ltd.

Bristol Myers Squibb Co.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (26 Sep 2024),

Schizophrenia

Regulation-

Structure

Molecular FormulaC14H23N3OS

InChIKeyJOLJIIDDOBNFHW-UHFFFAOYSA-N

CAS Registry131986-45-3

View All Structures (2)

Clinical Trials associated with Xanomeline Tartrate/Trospium Chloride

NCT06729970 / Not yet recruitingPhase 1

A Phase 1, 4-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Lithium and Valproic Acid on the Single-dose Pharmacokinetics of KarXT and Effects of KarXT on the Single-dose Pharmacokinetics of Lithium and Valproic Acid in Healthy Participants

The purpose of this study is to evaluate the effects of lithium and valproic acid on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium and valproic acid in healthy participants.

Start Date23 Dec 2024

Sponsor / Collaborator

Karuna Therapeutics, Inc.

NCT06572449 / RecruitingPhase 3

A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

Start Date28 Oct 2024

Sponsor / Collaborator

Karuna Therapeutics, Inc.

NCT06605950 / RecruitingPhase 1

A 2-Part, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride in Healthy Adult Participants (Part 2)

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.

Start Date01 Oct 2024

Sponsor / Collaborator

Karuna Therapeutics, Inc.

100 Clinical Results associated with Xanomeline Tartrate/Trospium Chloride

100 Translational Medicine associated with Xanomeline Tartrate/Trospium Chloride

100 Patents (Medical) associated with Xanomeline Tartrate/Trospium Chloride

Literatures (Medical) associated with Xanomeline Tartrate/Trospium Chloride

01 Jan 2025·JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis

Article

Author: Menegaz de Almeida, Artur ; Aquino de Moraes, Francisco Cezar ; Moraes Tamashiro, Fernanda ; Kelly, Francinny Alves ; de Almeida Souza Miranda, Celso ; Luiz Silvério, Iasmin Isabelli ; Cavalcanti Souza, Maria Eduarda ; Barros Andrade, Ítalo ; Kreuz, Michele

INTRODUCTION:

Schizophrenia is one of the psychiatric illnesses with a higher mortality rate. Xanomeline, an oral muscarinic receptor agonist, combined with Trospium, a pan-muscarinic receptor antagonist, represents a promising new treatment for schizophrenia that has been tested in clinical trials. Herein, we aimed to perform a meta-analysis assessing Xanomeline-Trospium Chloride's (XTC) safety and efficacy for treating schizophrenia.

MATERIALS AND METHODS:

MEDLINE, EMBASE, and Cochrane databases were searched for randomized clinical trials testing XTC safety and efficacy in patients with schizophrenia on May 03, 2024. The research protocol was registered with the International Prospective Register of Systematic Reviews (CRD42024547487). Data were examined using the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed using I² statistics. R, version 4.3.2, was used for statistical analysis.

RESULTS:

3 RCTs and 674 patients were included, of whom 332 (49%) received XTC. The change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score was significantly higher in the XTC arm (MD -13.17; 95% CI -20.16 to -6.18; P = 0.0002; I² = 100%). Treatment with XTC resulted in improvements across all subscales of the PANSS. Additionally, XTC was associated with the occurrence of cholinergic adverse events, including nausea (18,52% vs. 3,79%; RR 4.37; 95% CI 2.43 to 7.84; P < 0.000001; I² = 19%) but was not associated with akathisia (MD -0.00; 95% CI -0.13 to 0.13; P = 0.9; I² = 0%) or body weight gain (MD -0.36; 95% CI -1.18 to 0.46; P = 0.38; I² = 51%).

CONCLUSION:

XTC is effective in improving schizophrenia symptoms. However, it is associated with some bothersome AEs that may undermine its tolerability and lead to increased discontinuation rates, despite its efficacy.

01 Dec 2024·SCHIZOPHRENIA RESEARCH

Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials

Article

Author: Targum, Steven D ; Kaul, Inder ; Horan, William P ; Miller, Andrew C. ; Brannan, Stephen K. ; Targum, Steven D. ; Horan, William P. ; Yohn, Samantha E. ; Yohn, Samantha E ; Claxton, Amy ; Marder, Stephen R ; Miller, Andrew C ; Marder, Stephen R. ; Brannan, Stephen K

BACKGROUND:

Currently approved antipsychotics do not adequately treat negative symptoms (NS), which are a major determinant of functional disability in schizophrenia. KarXT, an M₁ /M₄ preferring muscarinic receptor agonist, has shown efficacy as a broad-spectrum monotherapy for the treatment of schizophrenia in participants with acute psychosis. Post hoc analyses evaluated the possibility that NS improve independently of positive symptoms with KarXT in a subgroup of participants with moderate-to-severe NS and no predominance of positive symptoms.

METHODS:

Data were pooled from the three pivotal trials of KarXT monotherapy in people with schizophrenia with an acute exacerbation of psychosis. All 3 studies used similar 5-week randomized, double-blind, placebo-controlled designs (modified intention-to-treat sample N = 640). PANSS criteria proposed in the literature identified a subset of study participants (n = 64) with prominent NS.

RESULTS:

KarXT was significantly better than placebo on PANSS Marder Negative Factor Scores in the full sample (p < .001; Cohen's d = 0.42) and more so in the prominent NS subgroup (p < .001; Cohen's d = 1.18). Further, the KarXT effect in the NS subgroup remained significant after accounting for changes in positive symptoms, depression/anxiety, disorganization, and hostility.

CONCLUSIONS:

Participants with prominent NS revealed greater improvement of NS following KarXT therapy than the full sample that persisted after accounting for positive and other symptoms. While these findings must be interpreted with caution, they are consistent with the possibility that NS improvements associated with KarXT are not secondary to improvements in other symptom domains and support further investigation in larger, stable outpatient studies.

01 Dec 2024·PHARMACOLOGICAL RESEARCH

IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia

Review

Author: Dean, Brian

Cobenfy, a co-formulation of xanomeline and trospium, is the first drug not acting on the dopaminergic system of the CNS approved for the treatment of schizophrenia by the FDA. Xanomeline is a muscarinic M1 and M4 receptor (CHRM1 and CHRM4) agonist whilst trospium is a peripherally active CHRM antagonist that reduces the unwanted peripheral side-effects of xanomeline. Relevant to this exciting development, this review details the human CNS cholinergic systems and how those systems are affected by the molecular pathology of schizophrenia in a way suggesting activating the CHRM1 and 4 would be beneficial in treating the disorder. The CNS distribution of CHRMs is presented along with findings using CHRM knockout mice and mice treated with drugs that activate the CHRM1 and / or M4, these data explain why these CHRMs could be involved in the genesis of the symptoms of schizophrenia. Next, the process leading to the formulation of Cobenfy and the preclinical data on xanomeline are reviewed showing why Cobenfy was expected to be useful in treating schizophrenia. The pipeline of drugs targeting CHRM1 and /or M4 receptors to treat schizophrenia are discussed. Finally, the molecular pathology of two sub-groups within schizophrenia, separated based on the presence or absence of a deficit of cortical CHRM1, are reviewed to show how such approaches could identify new drug targets. In conclusion, the history of the development of Cobenfy highlights how a growing understanding the pathophysiology of schizophrenia will suggest new treatment targets for the disorder and that pharmacologists can synthesise drugs to target these sites.

209

News (Medical) associated with Xanomeline Tartrate/Trospium Chloride

11 Dec 2024

·www.businesswire.com

Adams Clinical Announces Expansion into Inpatient Psychiatry and Schizophrenia Clinical Trial Capabilities with Signing of Partnership with InSite Clinical Research

BOSTON--( BUSINESS WIRE )--Adams Clinical, LLC (“Adams”, or the “Company”), a leading Neuroscience-focused clinical trial site network announced today that it has agreed on terms of the intent to partner with InSite Clinical Research (“InSite”), a clinical trial site in the Dallas-Fort Worth metroplex with expertise in inpatient and outpatient clinical trials for psychiatric and neurologic illnesses, including Schizophrenia. In parallel with this partnership, Adams Clinical is expanding inpatient capabilities to its existing Watertown, MA and Bronx, NY sites. The Company expects both locations to begin screening inpatient participants in the first half of 2025, augmenting Adams’ market-leading capabilities in outpatient Psychiatry and Alzheimer’s Disease treatment and prevention trials. “InSite adds an important dimension to our business as it expands Adam’s disease area expertise and marks the Company’s entry into Texas,” said Nelson Rutrick, CEO of Adams Clinical. “Historically, Adams Clinical focused only on Depression, outpatient Psychiatry, and Alzheimer’s Disease. Dr. Shiwach and the entire InSite team are widely regarded by pharmaceutical and biotech industry sponsors as a leader in acute Schizophrenia, Bipolar Disorder and Substance Use Disorder research. Dr. Shiwach and InSite are well-known for their contributions in many successful clinical trials that have led to new drug approvals over the last 20 years.” Mehran Ahmed, Partner at InTandem Capital Partners, added, “InSite has developed a strong track record in finding participants in this growing therapeutic area and we are excited to partner with InSite to further enhance their capabilities.” “I am delighted to join the Adams Clinical network and bring opportunities for additional clinical trials to the diverse psychiatric and neurological patient population that we serve here in Texas,” said Dr. Raj Shiwach, Principal Investigator at InSite. “I look forward to sharing my clinical expertise to replicate our successful inpatient Schizophrenia trial delivery model in the Massachusetts and New York locations.” Dr. Steve Brannan, an industry veteran in Schizophrenia drug development who most recently led the clinical development and successful FDA submission of Cobenfy (xanomeline & trospium chloride, formerly known as KarXT) as Chief Medical Officer of Karuna Therapeutics, said, “Dr. Shiwach made a substantial enrollment contribution in our Phase 2 and 3 KarXT trials. There continues to be an enormous unmet need for effective new therapies for people living with Schizophrenia and other psychiatric illnesses. The many promising new treatments in development across industry will necessitate an increase in clinical research sites capable of conducting high-quality inpatient and outpatient Psychiatry trials for the foreseeable future. The acquisition of InSite and the establishment of inpatient units at the existing Boston and New York City locations underscores Adams Clinical’s strategic alignment with the needs and priorities of their pharmaceutical and biotech sponsor customers.” The partnership with InSite follows a series of strategic expansion steps Adams Clinical has undertaken in 2024, including doubling existing site capacity with the opening of new site locations in New York City with Davis Clinical in the Bronx and Berman Clinical in Harlem. Provident Healthcare Partners served as the exclusive financial advisor to InSite Clinical in this transaction. About Adams Clinical Adams Clinical is the preeminent site network for enrollment speed and data quality in clinical trials for diseases of the central nervous system, with clinical trial sites embedded in vibrant, diverse communities throughout the US. The Company’s depth of expertise, best-in-class technologies, and market-leading recruitment and retention to accelerate high-quality evidence generation and time-to-data for Pharmaceutical and Biotech companies, CROs and clinical trial participants. About InTandem Capital Partners InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value working collaboratively with its management team partners. InTandem is solely focused on investing in businesses that align closely with the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery. The firm is comprised of former business executives and experienced investors, and is uniquely qualified to provide strategic, acquisition and operating expertise to help companies significantly increase their value and their contribution to an improved healthcare system. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities. For further information, please visit: www.intandemcapital.com .

Phase 2Acquisition

16 Nov 2024

·endpts.com

Trump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving off Summit; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . President-elect Donald Trump made good on his pledge to let Robert F. Kennedy Jr. “go wild on health,” nominating him as HHS secretary. For more on what this will mean for biopharma, read below, and keep checking back at Endpoints where our reporters will continue to have the latest. — Max Gelman RFK Jr. picked to lead HHS As Trump picked Robert F. Kennedy Jr. to be the next HHS secretary, Kennedy, a longtime anti-vaccine advocate, has said he will push for big changes at the FDA and NIH. At an event earlier this week, current FDA Commissioner Rob Califf weighed in on how the agency may be affected by the next administration, making pointed remarks about risks to its authority and workforce. When asked who might replace him, Califf said, “Hopefully it’ll be someone who understands the really critical role of high-quality evidence in everything we do.” AbbVie has a bad Monday The centerpiece of AbbVie’s $8.7 billion Cerevel buyout imploded on Monday, with the schizophrenia drug emraclidine registering not one, but two pivotal trial failures. Emraclidine had been expected to compete with Cobenfy , the newly approved drug from Bristol Myers Squibb and Karuna , but now it appears Cobenfy will have more of the market to itself. The news sent AbbVie’s stock down more than 12%, while BMS shares rose roughly 10%. Merck aims to keep Summit at arm’s length With Summit Therapeutics hot on its heels, the Keytruda developer spent $588 million upfront to get an exclusive global license to a PD-1/VEGF combination therapy called LM-299 , currently in Phase 1. The asset comes from LaNova Medicines , a startup based in Shanghai that can receive up to $2.7 billion in biobucks from the deal. Merck is attempting to stay in front of Summit and Akeso’s ivonescimab , which beat Keytruda in a Phase 3 lung cancer study earlier this year. 23andMe shuts down therapeutics division DNA testing company 23andMe announced this week that it’s closing its therapeutics division and winding down ongoing clinical trials. It’s also cutting 40% of its workforce or more than 200 employees. The move is the latest in a string of setbacks for 23andMe, including a data breach last year that affected millions of customers. The company said it’s exploring a range of options for offloading its therapeutic programs, including licensing agreements, asset sales or other deals. Aurion and its investor Alcon enter legal battle Cell therapy startup Aurion and its investor Alcon are engaged in an unusual legal spat after Alcon sued the biotech as it prepares to go public. While Alcon claimed its shareholder rights were being violated, Aurion argued in a counterclaim that Alcon “opposes the IPO because it interferes with Alcon’s plans to acquire Aurion at a discount.” The stakes are high for Aurion, which said its cash runway only extends to March, putting urgency on its plan to go public in January. SPOTLIGHT MORE IN R&D MORE IN PHARMA MORE IN FDA+ MORE IN STARTUPS MORE IN PEOPLE MORE IN MANUFACTURING MORE IN HEALTH TECH

AcquisitionPhase 3Vaccine

14 Nov 2024

·endpts.com

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

Plus, news about Allogene, Telix, Cullgen, Pulmatrix, Gilead, Innocoll, Durect and Sensei: Zai Lab’s $200M offering: The Shanghai-based drugmaker is selling shares the same week as announcing revenue growth of 47% year-over-year. It also said it plans to submit the schizophrenia drug KarXT for approval in China “early” next year. The FDA in September approved the medicine, owned by Bristol Myers Squibb. — Kyle LaHucik Kronos Bio to seek “strategic alternatives”: The company made the decision after looking at the data for a CDK9 inhibitor called istisociclib and deeming “the benefit-risk profile” as not warranting additional development. Istisociclib was designed to treat platinum-resistant high-grade serous ovarian cancer. Kronos had $124.9 million in cash, cash equivalents and investments as of the end of September. — Max Gelman Allogene halts enrollment in Phase 1 leukemia trial: The company was investigating cemacabtagene in patients with relapsed or refractory chronic lymphocytic leukemia. In its latest securities filing, Allogene blamed slow enrollment and “the emergence of new alternative treatment options” for its decision to halt enrollment altogether. The company added that it would be reallocating resources from the trial to other programs. Its shares $ALLO were down about 6% on Thursday morning. — Katherine Lewin Telix’s Nasdaq debut : The Australian radiopharma started trading on the Nasdaq as $TLX on Thursday. The company didn’t sell any new shares as part of the listing, though. It had pulled its Nasdaq IPO plans in the 11th hour in June. — Kyle LaHucik Cullgen to take Pulmatrix’s spot: Cullgen and the Nasdaq-listed Pulmatrix will reverse merge in a deal expected to close by the end of March. Cullgen makes protein degraders and degrader-antibody conjugates, or DACs, that are in Phase 1. Another DAC maker, Orum Therapeutics, is looking to go public , but in South Korea. Pre-merger Cullgen stockholders will get about 96.4% of the combined company. — Kyle LaHucik Gilead lays off 72 workers in Seattle: The cuts were attributed to a site closure and are set to begin in January, according to a WARN notice in Washington state. A spokesperson for Gilead did not immediately respond to a request for comment. The pharma gained a foothold in the Seattle area after acquiring Corus Pharma for $365 million in 2006. — Max Bayer Innocoll Pharmaceuticals ends licensing pact with Durect: Durect said the termination is effective in May. Innocoll had snagged US commercial rights to Durect’s non-opioid analgesic in December 2021. — Max Bayer Sensei to lay off 46% of staff, close research site in Rockville, MD: The cuts will extend Sensei’s runway into 2026, the company said. They will also help Sensei “focus resources on advancing the clinical development of SNS-101,” which the company is developing both as a monotherapy and a combination in advanced solid tumors. It had 27 employees as of Feb. 23. Its stock $SNSE fell about 11% on Thursday morning. — Max Gelman

Phase 1Drug ApprovalLicense out/inAcquisition

100 Deals associated with Xanomeline Tartrate/Trospium Chloride

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	US	Bristol Myers Squibb Co.	26 Sep 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute schizophrenia	Phase 3	CN	Zai Lab (Shanghai) Co., Ltd.	29 May 2023
Acute schizophrenia	Phase 3	CN	Karuna Therapeutics, Inc.	29 May 2023
Alzheimer Disease	Phase 3	US	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	BG	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	HR	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	CZ	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	FR	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	DE	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	IT	Karuna Therapeutics, Inc.	23 Aug 2022
Alzheimer Disease	Phase 3	RS	Karuna Therapeutics, Inc.	23 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04820309 (EMERGENT-5, Company_Website) Manual	Phase 3	Schizophrenia	566	COBENFY	wtnabfesgz(orpfxsybjr) = uoflqnlsak nhkzgvxnkg (eygkzuqyby ) View more	Positive	31 Oct 2024
NCT04659174 (EMERGENT-4, Company_Website) Manual	Phase 3	Schizophrenia	156	COBENFY	fdefptubdw(rodcvsqrwo) = knhzapymso nzjesenxfz (pudsyqegee )	Positive	31 Oct 2024
				Placebo	-
NCT04659174 (EMERGENT-4, CTgov)	Phase 3	Schizophrenia	152	KarXT (KarXT Arm A)	evrdunvopw(efsrllqykg) = mbcqqjaull qtnumubqxp (ngmhapfcqx, saitgvpzfk - ccsoompqaj) View more	-	28 Oct 2024
				Placebo+KarXT (KarXT Arm B)	evrdunvopw(efsrllqykg) = iqbzjpbikf qtnumubqxp (ngmhapfcqx, vuinuhoqsc - hebmfdatyc) View more
NCT04659161 (FDA_CDER) Manual	Phase 3	Schizophrenia	236	COBENFY	spbozmsydh(anealniwzg) = qknzsnczub lqyggvdgmo (jahaafimpd, 1.7)	Positive	26 Sep 2024
				Placebo	spbozmsydh(anealniwzg) = xxpbbjiklb lqyggvdgmo (jahaafimpd, 1.6)
NCT05643170 (PENNANT, CTgov)	Phase 3	Schizophrenia	4	Trospium Chloride Capsules	gkejdemypd(tgbbrxqpsa) = bbudwwlbhj qpudxyaudh (rdqpbznayz, bxbqbwgdei - hvebfgnxzt) View more	-	12 Jun 2024
NCT04659174 (EMERGENT-4, Corporate Publications) Manual	Phase 3	Schizophrenia	110	KarXT	mixopjxwtc(qgjiswhrum) = wwjoxiaopp ikdadkrzet (hjrzhoddbo ) View more	Positive	06 Apr 2024
NCT04659174 \| NCT04820309 (EMERGENT-5, Corporate Publications) Manual	Phase 3	Schizophrenia	718	KarXT	ahhthucvkf(jucluaxrev) = 62% of participants reported at least one. The most common treatment-related adverse events (≥5%) were nausea, vomiting, constipation, dry mouth, dyspepsia, dizziness, hypertension, and diarrhea, of which nearly all were mild or moderate in severity and transient in nature. wpowqdhgcm (mynrinxllm ) View more	Positive	06 Apr 2024
EMERGENT-3 (NEWS) Manual	Clinical	Schizophrenia	314	KarXT (EMERGENT-1)	laxiipojyj(gjgpnlkhqp) = hvgiqssfxa ddymrsytwh (qflargjzjg ) View more	Positive	08 Jan 2024
				placebo (EMERGENT-1)	laxiipojyj(gjgpnlkhqp) = arovmohbfm ddymrsytwh (qflargjzjg ) View more
NCT04659161 (EMERGENT-2, Corporate Publications) Manual	Phase 3	Schizophrenia	252	KarXT	bxookageyi(gfquzizold) = mxyjougiew wklvbtyhtj (wqnjffnzjg ) View more	Positive	14 Dec 2023
				Placebo	bxookageyi(gfquzizold) = yprqdlraui wklvbtyhtj (wqnjffnzjg ) View more
NCT04659161 (EMERGENT-2, CTgov)	Phase 3	Schizophrenia \| Psychotic Disorders	252	Trospium Chloride Capsules (KarXT)	bnlctjaibg(kuddldeqmw) = ddhbmcsjtg ecevjjgjtm (zwugryvewu, sezziqimcg - plyojdozyk) View more	-	12 Dec 2023
				Placebo (Placebo)	bnlctjaibg(kuddldeqmw) = ctskhmuajl ecevjjgjtm (zwugryvewu, adnzrkavrd - kslsuxqxmk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Xanomeline Tartrate/Trospium Chloride

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation